Personalis shows promise in cancer detection but is years away from profitability. Read why PSNL stock is rated a hold with ...

Blueprint Medicines (BPMC) sees strong AYVAKIT growth, 2025 revenue guidance at $680M-$710M. Discover insights on their market expansion & $2B 2030 vision.

TD Cowen analyst Yaron Werber raised the firm’s price target on Ascendis Pharma (ASND) to $162 from $153 and keeps a Buy rating on the shares.

If a language can be used to build web scrapers, it definitely needs to provide a graceful data visualization library. --- by dongdong. In the Golang ecosystem, there are not many choices for data ...